Exploring the Complex Relationship between Diabetes and Cardiovascular Complications: Understanding Diabetic Cardiomyopathy and Promising Therapies
暂无分享,去创建一个
R. Kandimalla | S. Dewanjee | Sagnik Nag | N. Ghosh | Jayalakshmi Vallamkondu | P. Reddy | Tanushree Karmakar | A. Dey | Hiranmoy Bhattacharya | Abhijit Dey | Nilanjan Ghosh | Leena Chacko | Hiranmoy Bhattacharya | Jayalakshmi Vallamkondu | Sagnik Nag | Tanushree Karmakar | P. Hemachandra Reddy | Ramesh Kandimalla | Saikat Dewanjee | Leena Chacko | Abhijit Dey | Ramesh Kandimalla | Nilanjan Ghosh | Leena Chacko | P. H. Reddy
[1] K. Naka,et al. The effect of SGLT2 inhibitors, GLP1 agonists, and their sequential combination on cardiometabolic parameters: A randomized, prospective, intervention study. , 2023, Journal of diabetes and its complications.
[2] M. Maleki,et al. Cognitive benefits of Sodium-Glucose Co-Transporters-2 Inhibitors in the Diabetic Milieu. , 2023, Current medicinal chemistry.
[3] A. Sahebkar,et al. Advances in the Pharmacological Management of Diabetic Nephropathy: A 2022 International Update , 2023, Biomedicines.
[4] S. Patil,et al. Suppression of Tumorigenicity 2 Pro-Inflammatory Biomarker Linking Diabetes Mellitus and Periodontitis: A Pilot Study , 2022, Medical science monitor : international medical journal of experimental and clinical research.
[5] D. D’Alessio,et al. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction , 2022, Cardiovascular Diabetology.
[6] Yang Zhang,et al. Plin5, a New Target in Diabetic Cardiomyopathy , 2022, Oxidative medicine and cellular longevity.
[7] Yue Cheng,et al. Mitochondria-Endoplasmic Reticulum Contacts: The Promising Regulators in Diabetic Cardiomyopathy , 2022, Oxidative medicine and cellular longevity.
[8] B. Geest,et al. Role of Oxidative Stress in Diabetic Cardiomyopathy , 2022, Antioxidants.
[9] A. Cudnoch-Jędrzejewska,et al. Remodeling and Fibrosis of the Cardiac Muscle in the Course of Obesity—Pathogenesis and Involvement of the Extracellular Matrix , 2022, International journal of molecular sciences.
[10] P. Light,et al. Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects. , 2022, Journal of molecular and cellular cardiology.
[11] C. Maack,et al. Mitochondria as Therapeutic Targets in Heart Failure , 2022, Current Heart Failure Reports.
[12] M. Maiorino,et al. Glycemic Control and the Heart: The Tale of Diabetic Cardiomyopathy Continues , 2022, Biomolecules.
[13] Ramakrishnan Veerabathiran,et al. Genetic predisposition study of heart failure and its association with cardiomyopathy , 2022, The Egyptian Heart Journal.
[14] F. Romeo,et al. Mechanisms of cardiac dysfunction in diabetic cardiomyopathy: molecular abnormalities and phenotypical variants , 2022, Heart Failure Reviews.
[15] K. Kitamura,et al. Translational studies of adrenomedullin and related peptides regarding cardiovascular diseases , 2022, Hypertension Research.
[16] P. Winocour,et al. Management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease: Association of British Clinical Diabetologists and the Renal Association UK guideline update 2021 , 2022, BMC Nephrology.
[17] R. Kaur,et al. Protective effect of rosuvastatin pretreatment against acute myocardial injury by regulating Nrf2, Bcl-2/Bax, iNOS, and TNF-α expressions affecting oxidative/nitrosative stress and inflammation , 2022, Human & experimental toxicology.
[18] Nor Azian Abdul Murad,et al. Coronary Heart Disease in Type 2 Diabetes Mellitus: Genetic Factors and Their Mechanisms, Gene-Gene, and Gene-Environment Interactions in the Asian Populations , 2022, International journal of environmental research and public health.
[19] L. Cai,et al. Ferroptosis is essential for diabetic cardiomyopathy and is prevented by sulforaphane via AMPK/NRF2 pathways , 2021, Acta pharmaceutica Sinica. B.
[20] Xin-Fu Zhou,et al. Novel oral edaravone attenuates diastolic dysfunction of diabetic cardiomyopathy by activating the Nrf2 signaling pathway. , 2021, European journal of pharmacology.
[21] Jin Han,et al. Current status on the therapeutic strategies for heart failure and diabetic cardiomyopathy. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[22] Q. Ning,et al. IUGR with catch-up growth programs impaired insulin sensitivity through LRP6/IRS-1 in male rats , 2021, Endocrine connections.
[23] Yuehua Jiang,et al. Quercetin Attenuates Cardiac Hypertrophy by Inhibiting Mitochondrial Dysfunction Through SIRT3/PARP-1 Pathway , 2021, Frontiers in Pharmacology.
[24] A. Lombardi,et al. Heart failure in diabetes. , 2021, Metabolism: clinical and experimental.
[25] T. Lüscher,et al. Inflammation in Metabolic Cardiomyopathy , 2021, Frontiers in Cardiovascular Medicine.
[26] C. Lang,et al. Left Ventricular Hypertrophy in Diabetic Cardiomyopathy: A Target for Intervention , 2021, Frontiers in Cardiovascular Medicine.
[27] E. Ferrannini,et al. Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence , 2021, Cardiovascular Diabetology.
[28] J. Corbett,et al. The Role of Thioredoxin/Peroxiredoxin in the β-Cell Defense Against Oxidative Damage , 2021, Frontiers in Endocrinology.
[29] M. Michal,et al. Disturbed Glucose Metabolism and Left Ventricular Geometry in the General Population , 2021, Journal of clinical medicine.
[30] Tongzhi Wu,et al. Lactate and Myocardiac Energy Metabolism , 2021, Frontiers in Physiology.
[31] M. Brans,et al. Neutral Effects of Combined Treatment With GLP-1R Agonist Exenatide and MR Antagonist Potassium Canrenoate on Cardiac Function in Porcine and Murine Chronic Heart Failure Models , 2021, Frontiers in Pharmacology.
[32] James D. Johnson. On the causal relationships between hyperinsulinaemia, insulin resistance, obesity and dysglycaemia in type 2 diabetes , 2021, Diabetologia.
[33] Ling-Qing Yuan,et al. Ferroptosis and Its Potential Role in Metabolic Diseases: A Curse or Revitalization? , 2021, Frontiers in Cell and Developmental Biology.
[34] G. Booz,et al. Atrial Natriuretic Peptide31–67: A Novel Therapeutic Factor for Cardiovascular Diseases , 2021, Frontiers in Physiology.
[35] A. Pfeiffer,et al. The evolving story of incretins (GIP and GLP‐1) in metabolic and cardiovascular disease: A pathophysiological update , 2021, Diabetes, obesity & metabolism.
[36] E. Gozal,et al. Cardiac metallothionein overexpression rescues diabetic cardiomyopathy in Akt2‐knockout mice , 2021, Journal of cellular and molecular medicine.
[37] R. Tian,et al. Cardiac Energy Metabolism in Heart Failure , 2021, Circulation research.
[38] P. Little,et al. GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential , 2021, International journal of biological sciences.
[39] C. Ferran,et al. A20/TNFAIP3 Increases ENOS Expression in an ERK5/KLF2-Dependent Manner to Support Endothelial Cell Health in the Face of Inflammation , 2021, Frontiers in Cardiovascular Medicine.
[40] Jun Ren,et al. Obesity cardiomyopathy: evidence, mechanisms, and therapeutic implications , 2021, Physiological reviews.
[41] S. Menini,et al. Diabetic Complications and Oxidative Stress: A 20-Year Voyage Back in Time and Back to the Future , 2021, Antioxidants.
[42] S. Khaliq,et al. Dysregulation of circulating miRNAs promotes the pathogenesis of diabetes-induced cardiomyopathy , 2021, PloS one.
[43] E. Abel,et al. Therapeutic potential of targeting oxidative stress in diabetic cardiomyopathy. , 2021, Free Radical Biology & Medicine.
[44] Z. Giricz,et al. Natural and synthetic antioxidants targeting cardiac oxidative stress and redox signaling in cardiometabolic diseases. , 2021, Free radical biology & medicine.
[45] Chiadi E. Ndumele,et al. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association , 2021, Circulation.
[46] Xiao-hong Tang,et al. High-mobility group box 1 serves as an inflammation driver of cardiovascular disease. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[47] Arturo Santos,et al. Molecular Mechanisms of Obesity-Linked Cardiac Dysfunction: An Up-Date on Current Knowledge , 2021, Cells.
[48] M. Banach,et al. Effects of statins on myocarditis: A review of underlying molecular mechanisms. , 2021, Progress in cardiovascular diseases.
[49] M. Bin-Jumah,et al. Quercetin prevents myocardial infarction adverse remodeling in rats by attenuating TGF-β1/Smad3 signaling: Different mechanisms of action , 2021, Saudi journal of biological sciences.
[50] W. Ding,et al. Nlrp3 Deficiency Alleviates Angiotensin II-Induced Cardiomyopathy by Inhibiting Mitochondrial Dysfunction , 2021, Oxidative medicine and cellular longevity.
[51] Manisha Pandey,et al. Molecular and Biochemical Pathways of Catalpol in Alleviating Diabetes Mellitus and Its Complications , 2021, Biomolecules.
[52] V. Demarco,et al. Sacubitril/valsartan inhibits obesity-associated diastolic dysfunction through suppression of ventricular-vascular stiffness , 2021, Cardiovascular Diabetology.
[53] C. Cheung,et al. Impact of peroxisome proliferator-activated receptor-α on diabetic cardiomyopathy , 2021, Cardiovascular Diabetology.
[54] E. Brady,et al. Sex and ethnic differences in the cardiovascular complications of type 2 diabetes , 2021, Therapeutic advances in endocrinology and metabolism.
[55] Murugesan V. S. Rajaram,et al. Role of Cardiac Macrophages on Cardiac Inflammation, Fibrosis and Tissue Repair , 2020, Cells.
[56] N. Nair. Epidemiology and pathogenesis of heart failure with preserved ejection fraction. , 2020, Reviews in cardiovascular medicine.
[57] E. Fontaine,et al. Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes , 2020, Diabetes, obesity & metabolism.
[58] J. Aran,et al. Reactive Oxygen Species: Drivers of Physiological and Pathological Processes , 2020, Journal of inflammation research.
[59] V. Fuster,et al. The Global Burden of Cardiovascular Diseases and Risks: A Compass for Global Action. , 2020, Journal of the American College of Cardiology.
[60] A. Allam,et al. Edaravone and Acetovanillone Upregulate Nrf2 and PI3K/Akt/mTOR Signaling and Prevent Cyclophosphamide Cardiotoxicity in Rats , 2020, Drug design, development and therapy.
[61] P. Ponikowski,et al. Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status , 2020, Circulation.
[62] D. Moller,et al. Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action , 2020, bioRxiv.
[63] N. Chattipakorn,et al. Contrast-induced nephropathy and oxidative stress: mechanistic insights for better interventional approaches , 2020, Journal of translational medicine.
[64] M. Syamsunarno,et al. DPP-4 inhibitor induces FGF21 expression via sirtuin 1 signaling and improves myocardial energy metabolism , 2020, Heart and Vessels.
[65] F. Ferdousi,et al. Effects of Isorhamnetin in Human Amniotic Epithelial Stem Cells in vitro and Its Cardioprotective Effects in vivo , 2020, Frontiers in Cell and Developmental Biology.
[66] Yulan Zhang,et al. Endothelial Dysfunction in Diabetic Retinopathy , 2020, Frontiers in Endocrinology.
[67] César Martín,et al. Pathophysiology of Type 2 Diabetes Mellitus , 2020, International journal of molecular sciences.
[68] P. Ponikowski,et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. , 2020, The New England journal of medicine.
[69] G. Filippatos,et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials , 2020, The Lancet.
[70] J. Fruchart,et al. Selective Peroxisome Proliferator–Activated Receptor Alpha Modulators (SPPARMα): New Opportunities to Reduce Residual Cardiovascular Risk in Chronic Kidney Disease? , 2020, Current Atherosclerosis Reports.
[71] M. Sharifi-Rad,et al. Lifestyle, Oxidative Stress, and Antioxidants: Back and Forth in the Pathophysiology of Chronic Diseases , 2020, Frontiers in Physiology.
[72] A. Zorzano,et al. Neuregulin, an Effector on Mitochondria Metabolism That Preserves Insulin Sensitivity , 2020, Frontiers in Physiology.
[73] Xuan Chen,et al. Inhibition of miR-223 attenuates the NLRP3 inflammasome activation, fibrosis, and apoptosis in diabetic cardiomyopathy. , 2020, Life sciences.
[74] R. Ritchie,et al. Basic Mechanisms of Diabetic Heart Disease. , 2020, Circulation research.
[75] D. Gruson,et al. Soluble ST2: a complex and diverse role in several diseases. , 2020, Clinica chimica acta; international journal of clinical chemistry.
[76] R. Pratley,et al. GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials , 2020, Frontiers in Endocrinology.
[77] D. Prakoso,et al. Enhanced Cardiac Phosphoinositide 3-Kinase (p110α) using Gene Therapy Attenuates Cardiac Remodeling in Type 2 Diabetic Mice. , 2020, American journal of physiology. Heart and circulatory physiology.
[78] L. Cai,et al. Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence , 2020, Nature Reviews Cardiology.
[79] N. Kaludercic,et al. Mitochondrial ROS Formation in the Pathogenesis of Diabetic Cardiomyopathy , 2020, Frontiers in Cardiovascular Medicine.
[80] Tianhui You,et al. A Synthetic Curcuminoid Analog, (2E,6E)-2,6-bis(2-(trifluoromethyl)benzylidene)cyclohexanone, Ameliorates Impaired Wound Healing in Streptozotocin-Induced Diabetic Mice by Increasing miR-146a , 2020, Molecules.
[81] A. Trafford,et al. The Control of Diastolic Calcium in the Heart , 2020, Circulation research.
[82] V. Conti,et al. Cardioprotective Effects of Dietary Phytochemicals on Oxidative Stress in Heart Failure by a Sex-Gender-Oriented Point of View , 2020, Oxidative medicine and cellular longevity.
[83] M. Treppendahl,et al. Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk , 2020, Diabetes, obesity & metabolism.
[84] K. Sliwa,et al. Acute heart failure , 2008, Nature Reviews Disease Primers.
[85] J. Salazar,et al. Neprilysin: A Potential Therapeutic Target of Arterial Hypertension? , 2020, Current cardiology reviews.
[86] A. Mattiazzi,et al. Unbalance Between Sarcoplasmic Reticulum Ca2 + Uptake and Release: A First Step Toward Ca2 + Triggered Arrhythmias and Cardiac Damage , 2020, Frontiers in Physiology.
[87] J. Stamler,et al. Role of Nitric Oxide Carried by Hemoglobin in Cardiovascular Physiology: Developments on a Three-Gas Respiratory Cycle. , 2020, Circulation research.
[88] A. Murray,et al. Altered mitochondrial metabolism in the insulin‐resistant heart , 2019, Acta physiologica.
[89] G. Iacobellis,et al. Epicardial Adipose Tissue: Clinical Biomarker of Cardio-Metabolic Risk , 2019, International journal of molecular sciences.
[90] Zuyi Yuan,et al. Zinc supplementation protects against diabetic endothelial dysfunction via GTP cyclohydrolase 1 restoration. , 2019, Biochemical and biophysical research communications.
[91] A. M. Leone,et al. Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction , 2019, Front. Physiol..
[92] G. D. De Keulenaer,et al. Mechanisms of the Multitasking Endothelial Protein NRG-1 as a Compensatory Factor During Chronic Heart Failure. , 2019, Circulation. Heart failure.
[93] H. Grill,et al. Glucagon-like peptide 1 (GLP-1) , 2019, Molecular metabolism.
[94] Akshay S. Desai,et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.
[95] R. Touyz,et al. Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure , 2019, Pharmacological Reviews.
[96] J. Shaw,et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. , 2019, Diabetes research and clinical practice.
[97] A. Arya,et al. Endoplasmic Reticulum Stress Activates Unfolded Protein Response Signaling and Mediates Inflammation, Obesity, and Cardiac Dysfunction: Therapeutic and Molecular Approach , 2019, Front. Pharmacol..
[98] T. Vilsbøll,et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2019, The New England journal of medicine.
[99] E. Solá,et al. The Mitochondrial Antioxidant SS-31 Modulates Oxidative Stress, Endoplasmic Reticulum Stress, and Autophagy in Type 2 Diabetes , 2019, Journal of clinical medicine.
[100] Akshay S. Desai,et al. Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America. , 2019, Circulation.
[101] T. Arnould,et al. Mitochondrial Uncoupling: A Key Controller of Biological Processes in Physiology and Diseases , 2019, Cells.
[102] Jibo Han,et al. Kaempferol Prevents Against Ang II-induced Cardiac Remodeling Through Attenuating Ang II-induced Inflammation and Oxidative Stress , 2019, Journal of cardiovascular pharmacology.
[103] A. Lenzi,et al. Cardiomyopathy Associated with Diabetes: The Central Role of the Cardiomyocyte , 2019, International journal of molecular sciences.
[104] V. Fernandes,et al. Association between cardiovascular autonomic neuropathy and left ventricular hypertrophy in young patients with congenital generalized lipodystrophy , 2019, Diabetology & Metabolic Syndrome.
[105] D. H. Tran,et al. Glucose Metabolism in Cardiac Hypertrophy and Heart Failure , 2019, Journal of the American Heart Association.
[106] G. Liang,et al. Luteolin protects against diabetic cardiomyopathy by inhibiting NF-κB-mediated inflammation and activating the Nrf2-mediated antioxidant responses. , 2019, Phytomedicine : international journal of phytotherapy and phytopharmacology.
[107] P. Deedwania,et al. Cardiovascular Protection with Anti-hyperglycemic Agents , 2019, American Journal of Cardiovascular Drugs.
[108] N. Esser,et al. Neprilysin inhibition: a new therapeutic option for type 2 diabetes? , 2019, Diabetologia.
[109] M. Volpe,et al. ARNi: A Novel Approach to Counteract Cardiovascular Diseases , 2019, International journal of molecular sciences.
[110] Lulu Chen,et al. Serum triglycerides as a risk factor for cardiovascular diseases in type 2 diabetes mellitus: a systematic review and meta-analysis of prospective studies , 2019, Cardiovascular Diabetology.
[111] B. Hocher,et al. The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury , 2019, Kidney and Blood Pressure Research.
[112] Z. Cao,et al. BNP and NT-proBNP as Diagnostic Biomarkers for Cardiac Dysfunction in Both Clinical and Forensic Medicine , 2019, International journal of molecular sciences.
[113] Shanping Wang,et al. Trimetazidine prevents diabetic cardiomyopathy by inhibiting Nox2/TRPC3-induced oxidative stress. , 2019, Journal of pharmacological sciences.
[114] J. Goldberger,et al. Autonomic Nervous System Dysfunction: JACC Focus Seminar. , 2019, Journal of the American College of Cardiology.
[115] Maruf M. U. Ali,et al. Structure and Molecular Mechanism of ER Stress Signaling by the Unfolded Protein Response Signal Activator IRE1 , 2019, Front. Mol. Biosci..
[116] J. Badimón,et al. Metabolism of the failing heart and the impact of SGLT2 inhibitors , 2019, Expert opinion on drug metabolism & toxicology.
[117] N. Wong,et al. Epidemiology of Diabetes Mellitus and Cardiovascular Disease , 2019, Current Cardiology Reports.
[118] S. Shukla,et al. Proteasome biology and therapeutics in cardiac diseases , 2019, Translational research : the journal of laboratory and clinical medicine.
[119] Matthew J. Crowley,et al. Triglycerides: Emerging Targets in Diabetes Care? Review of Moderate Hypertriglyceridemia in Diabetes , 2019, Current Diabetes Reports.
[120] Angelos Liontos,et al. SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses , 2019, Postgraduate medicine.
[121] R. Eckel,et al. Statin Toxicity: Mechanistic Insights and Clinical Implications , 2019, Circulation research.
[122] A. Mebazaa,et al. Adrenomedullin in heart failure: pathophysiology and therapeutic application , 2018, European journal of heart failure.
[123] Deli Zhang,et al. Role of Autophagy in Proteostasis: Friend and Foe in Cardiac Diseases , 2018, Cells.
[124] A. Sposito,et al. GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data , 2018, Cardiovascular Diabetology.
[125] P. Newsholme,et al. Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function , 2018, Front. Endocrinol..
[126] J. Hecksher-Sørensen,et al. The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE−/− and LDLr−/− Mice by a Mechanism That Includes Inflammatory Pathways , 2018, JACC. Basic to translational science.
[127] S. Houser,et al. Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control , 2018, Front. Physiol..
[128] J. Herance,et al. The mitochondrial antioxidant SS-31 increases SIRT1 levels and ameliorates inflammation, oxidative stress and leukocyte-endothelium interactions in type 2 diabetes , 2018, Scientific Reports.
[129] Jian Sun,et al. Cardioprotective effects of the novel curcumin analogue C66 in diabetic mice is dependent on JNK2 inactivation , 2018, Journal of cellular and molecular medicine.
[130] S. Petak,et al. Cardiac Autonomic Neuropathy in Diabetes Mellitus. , 2018, Methodist DeBakey cardiovascular journal.
[131] A. Farcomeni,et al. Soluble ST2 is a biomarker for cardiovascular mortality related to abnormal glucose metabolism in high-risk subjects , 2018, Acta Diabetologica.
[132] D. Campbell,et al. Neprilysin Inhibitors and Bradykinin , 2018, Front. Med..
[133] Anil Poudel,et al. Diabetes and Associated Cardiovascular Complications in American Indians/Alaskan Natives: A Review of Risks and Prevention Strategies , 2018, Journal of diabetes research.
[134] J. Sowers,et al. Role of Renin-Angiotensin-Aldosterone System Activation in Promoting Cardiovascular Fibrosis and Stiffness , 2018, Hypertension.
[135] S. Cadenas. Mitochondrial uncoupling, ROS generation and cardioprotection. , 2018, Biochimica et biophysica acta. Bioenergetics.
[136] Claudio Aguayo,et al. Association between insulin resistance and the development of cardiovascular disease , 2018, Cardiovascular Diabetology.
[137] J. McMurray,et al. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review , 2018, Diabetologia.
[138] M. George,et al. Novel approaches in the treatment of diabetic cardiomyopathy. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[139] T. Einarson,et al. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017 , 2018, Cardiovascular Diabetology.
[140] A. Huqi,et al. Trimetazidine and Other Metabolic Modifiers. , 2018, European cardiology.
[141] Sang-Mo Kwon,et al. Pivotal Roles of Peroxisome Proliferator-Activated Receptors (PPARs) and Their Signal Cascade for Cellular and Whole-Body Energy Homeostasis , 2018, International journal of molecular sciences.
[142] N. Ghosh,et al. Molecular mechanism of diabetic cardiomyopathy and modulation of microRNA function by synthetic oligonucleotides , 2018, Cardiovascular Diabetology.
[143] J. Sowers,et al. Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity , 2018, Circulation research.
[144] G. Liang,et al. Kaempferol attenuates hyperglycemia-induced cardiac injuries by inhibiting inflammatory responses and oxidative stress , 2018, Endocrine.
[145] T. Biering-Sørensen,et al. Increased left ventricular mass index is present in patients with type 2 diabetes without ischemic heart disease , 2018, Scientific Reports.
[146] M. R. Prajapati,et al. Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor , 2018, Indian heart journal.
[147] John R. Petrie,et al. Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms , 2017, The Canadian journal of cardiology.
[148] C. Hetz,et al. The Unfolded Protein Response and Cell Fate Control. , 2017, Molecular cell.
[149] H. Young,et al. The SarcoEndoplasmic Reticulum Calcium ATPase. , 2018, Sub-cellular biochemistry.
[150] J. A. Nogueira-Machado,et al. Cellular death, reactive oxygen species (ROS) and diabetic complications , 2018, Cell Death & Disease.
[151] Jian Xiao,et al. Metallothionein Preserves Akt2 Activity and Cardiac Function via Inhibiting TRB3 in Diabetic Hearts , 2017, Diabetes.
[152] J. Udell,et al. Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials , 2017, Circulation.
[153] R. Seeley,et al. The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice , 2017, Molecular metabolism.
[154] H. Tomita,et al. Thioredoxin 2 Offers Protection against Mitochondrial Oxidative Stress in H9c2 Cells and against Myocardial Hypertrophy Induced by Hyperglycemia , 2017, International journal of molecular sciences.
[155] G. Ma,et al. Erythropoietin Attenuates Cardiac Dysfunction in Rats by Inhibiting Endoplasmic Reticulum Stress-Induced Diabetic Cardiomyopathy , 2017, Cardiovascular Drugs and Therapy.
[156] R. Guo,et al. Role of microRNA in diabetic cardiomyopathy: From mechanism to intervention. , 2017, Biochimica et biophysica acta. Molecular basis of disease.
[157] B. Staels. Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms. , 2017, The American journal of cardiology.
[158] K. Khunti,et al. Lower Risk of Heart Failure and Death in Patients Initiated on SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study , 2017 .
[159] A. Nandy,et al. Protocatechuic Acid, a Phenolic from Sansevieria roxburghiana Leaves, Suppresses Diabetic Cardiomyopathy via Stimulating Glucose Metabolism, Ameliorating Oxidative Stress, and Inhibiting Inflammation , 2017, Front. Pharmacol..
[160] Akshay S. Desai,et al. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. , 2017, The lancet. Diabetes & endocrinology.
[161] S. Bergante,et al. Effects of Polyphenols on Oxidative Stress-Mediated Injury in Cardiomyocytes , 2017, Nutrients.
[162] Wang-Soo Lee,et al. Diabetic cardiomyopathy: where we are and where we are going , 2017, The Korean journal of internal medicine.
[163] Z. Wang,et al. Isorhamnetin protects against cardiac hypertrophy through blocking PI3K–AKT pathway , 2017, Molecular and Cellular Biochemistry.
[164] T. Heise,et al. Improved Insulin Sensitivity With Angiotensin Receptor Neprilysin Inhibition in Individuals With Obesity and Hypertension , 2017, Clinical pharmacology and therapeutics.
[165] Qinghua Wang,et al. Cardiovascular Benefits of Native GLP-1 and its Metabolites: An Indicator for GLP-1-Therapy Strategies , 2017, Front. Physiol..
[166] W. Cefalu,et al. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus , 2016, Current opinion in endocrinology, diabetes, and obesity.
[167] P. Seferovic,et al. Heart Failure in Patients with Diabetes Mellitus. , 2016, Cardiac failure review.
[168] J. Shaw,et al. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. , 2011, Diabetes research and clinical practice.
[169] J. Sowers,et al. Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease , 2017, Diabetologia.
[170] Susmita Das,et al. Sansevieria roxburghiana Schult. & Schult. F. (Family: Asparagaceae) Attenuates Type 2 Diabetes and Its Associated Cardiomyopathy , 2016, PloS one.
[171] J. Russell,et al. Diabetes and Cognitive Impairment , 2016, Current Diabetes Reports.
[172] I. Arisi,et al. TIMP3 interplays with apelin to regulate cardiovascular metabolism in hypercholesterolemic mice , 2015, Molecular metabolism.
[173] Z. Kassiri,et al. Extracellular matrix communication and turnover in cardiac physiology and pathology. , 2015, Comprehensive Physiology.
[174] V. De Feo,et al. Abroma augusta L. (Malvaceae) leaf extract attenuates diabetes induced nephropathy and cardiomyopathy via inhibition of oxidative stress and inflammatory response , 2015, Journal of Translational Medicine.
[175] Iciar Martín-Timón,et al. Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength? , 2014, World journal of diabetes.
[176] P. Manning,et al. Cardiovascular microRNAs: as modulators and diagnostic biomarkers of diabetic heart disease , 2014, Cardiovascular Diabetology.
[177] N. Mochizuki,et al. Dipeptidyl-peptidase IV inhibition improves pathophysiology of heart failure and increases survival rate in pressure-overloaded mice. , 2013, American journal of physiology. Heart and circulatory physiology.
[178] J. González-Juanatey,et al. Coronary artery disease is associated with higher epicardial Retinol‐binding protein 4 (RBP4) and lower glucose transporter (GLUT) 4 levels in epicardial and subcutaneous adipose tissue , 2012, Clinical endocrinology.